🎯 Extending the Half-Life of mAbs: Why It Matters in IBD
In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems.
🧬 Enter Fc engineering: By tweaking the Fc region of antibodies, we can achieve:
✅ Longer half-life
✅ Reduced dosing frequency
✅ Better mucosal drug retention
✅ Lower immunogenicity risk
This fun cartoon breaks down 6 key Fc engineering strategies—including YTE, LS, LALA (Remember Risankizumab! ) , and catch-and-release—with direct applications for managing IBD.
Imagine future mAbs needing only 1 injection every 4-6 months or even longer, with less immune activation and greater mucosal healing. We're not far off!
GALAXI 2/3 just published in @TheLancet . Guselkumab superior to placebo and ustekinumab across multiple endpoints in mod-dev CD. The rigor of the trial design highlights how IBD trials need to be done to move the field forward. @bruce_sands1@IBDMD
https://t.co/f2STAeBD47
We had a phenomenal time strengthening relationships and focus on meaning in our work at our @SMCH_IBD_Celiac inaugural retreat. Thank you to @JonathanMoses77 and @hilaryjericho for leading the program, and to our amazing admin team for bringing us together for enrichment & fun!
🚀 Ready to lead, grow, + shape the future of @NASPGHAN? Now’s your moment and we need your spark 🔥- join a committee or run for a leadership role! Your voice matters + your ideas belong.✨ Step up. Lean in. Make an impact. #Leadership#CallToAction https://t.co/P2ncOJiVl2
Grateful to present our @SMCH_IBD_Celiac#IBDRISE study at @DDWMeeting!
Prev lit shows ⬆️ self-efficacy correlates with better transition to adult care & ⬆️ #psychosocial outcomes. Our study suggests #PeerSupport interventions like IBD RISE can be 🔑 to improving care in #PedsIBD
Congratulations to our amazing IBD Nurses on their poster presentation at the Society of Pediatric Nurses Annual Conference! Their work centered around enhancing nursing protocols for acutely symptomatic pediatric IBD patients on a national level! #SPN2025#PedsIBD
Excellent presentation by @patelperseus on IUS and biochemical remission in peds #IBD. BWT < 2.5, 2.4, 2.3 for UC, Ileal CD, Colon CD, respectively best cutpoints associated with calpro < 250. @SMCH_IBD_Celiac@StanfordPedsGI
Come learn from an amazing @StanfordMed student, Amy Bugwadia, presenting her wildly successful mentorship program to empower adolescents with #IBD in the Novel Interventions to Improve Psychosocial Outcomes session 4-5:30 29AB. #DDW2025@SMCH_IBD_Celiac@StanfordPedsGI
Super excited about our recent publication on Dual Targeted Therapy for the management of IBD with @jensemineriomd and @ZachMakovichMD@IBDJournals
https://t.co/2XllJ1SuyA
Exciting news! Our own Dr. Michael Rosen has been selected to serve as a Mentor for the Pediatric Coaching and Mentoring Program (PCAMP) starting Jan 1, 2025. This prestigious position was awarded from a large pool of highly competitive applicants.@DrRosenIBD
Congrats to @SMCH_IBD_Celiac faculty @patelperseus and @vivicality on their publication in @AGA_GHAdvances showing how AI LLMs can be used to accurately identify IBD symptoms in 2 EMRs from separate institutions! https://t.co/LNsfENsBo4
The NSAC Chair plays a key role in advising the Foundation leadership on strategy & vision for the Foundation’s activities, including research, education, support, and advocacy. Learn more about roles & responsibilities, requirements, timeline, and support https://t.co/SfcpnvLYwQ